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EM: erythema multiforme
IL: interleukin
LP: lichen planus
MMP: mucous membrane pemphigoid
PV: pemphigus vulgaris
TNF-a: tumor necrosis factor-aINTRODUCTION
Secukinumab is a new human monoclonal anti-
body targeting interleukin (IL)-17A, a cytokine
involved in the pathogenesis of psoriasis. The US
Food and Drug Administration approved secukinu-
mab for psoriasis in 2015. Because the medication
has been on the market for a short time, adverse
events involving the oral mucosa are rarely reported.
We report a case of severe, ulcerative, lichenoid
mucositis associated with secukinumab use.CASE REPORT
A 62-year-old white man underwent follow-up for
long-standing, intractable, erythrodermic psoriasis.
He did not respond to tumor necrosis factor (TNF)
inhibitors such as adalimumab and etanercept and
could not tolerate cyclosporine. Because metho-
trexate was only mildly efficacious, secukinumab
was added. Less than 1 week into secukinumab
treatment, very painful erosions and ulcers devel-
oped on the lower lip (Fig 1). The patient was taking
no other medications and had no history of recurrent
orolabial herpes simplex virus infection or other oral
disease such as aphthosis. Viral culture was negative
for herpes simplex virus. A potassium hydroxide
preparation and fungal culture were negative, and
lesions did not respond to oral fluconazole.
Because secukinumab was showing efficacy for
his psoriasis, and in the absence of a clear etiology of
the labial lesions, the patient elected to continue
taking the drug. The lesions persisted and remained
painful for 3 months, finally prompting discontinu-
ation of secukinumab. Shave biopsy found ulcera-
tion with a dense lichenoid inflammatory infiltrate
with scattered eosinophils, neutrophils, and plasmathe Department of Dermatologyc, Alpert Medical School of
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eet, Providence, RI 02903. E-mail: gk@gkderm.com.cells (Figs 2 and 3). The presence of eosinophils and
deeper inflammatory infiltrate (Fig 2) suggested a
lichenoid drug eruption. Direct immunofluores-
cence of perilesional mucosa found nonspecific
basal epithelium staining for C3, IgG, and IgM. The
patient started using 0.1% triamcinolone in Orabase
paste. It was not until approximately 6 weeks from
secukinumab discontinuation and 1 week of steroid
paste use that the labial lesions showed substantial
improvement.DISCUSSION
There are sparse reports of oral adverse events
associated with new antieIL-17 drugs (Table I).1-3
However, oral adverse effects of other biologic
agents such as TNF inhibitors, which have longer
track records, are well described (Table I).4-8 Mouth
ulceration was reported in 2 patients in a phase 2
secukinumab trial, but specifics were not provided.1
The differential diagnosis of our patient’s labial
lesions includes candidiasis, oral lichen planus
(LP), drug-induced LP, lichenoid contact dermatitis,
erythema multiforme (EM), major aphthae, complex
aphthosis, pemphigus vulgaris (PV), and mucous
membrane pemphigoid (MMP). Oral candidiasis,
reported in 1.8% of patients at 52 weeks in aJAAD Case Reports 2016;2:384-6.
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Fig 1. Multiple coalescing large ulcerations on an
erythematous base are shown on the vermillion and labial
mucosa.
Fig 2. Mucosal ulceration shows dense lichenoid infiltrate
with focal intact epithelium. (Hematoxylin-eosin stain;
original magnification: 3100.)
Fig 3. Eosinophils were noted throughout the inflamma-
tory infiltrate, including in the deep inflammatory infiltrate.
(Hematoxylin-eosin stain; original magnification, 3400.)
Table I. Oral adverse effects associated with anti-IL-
17 drugs and TNF-a inhibitors
Drug class Adverse effect
AntieIL-17 drugs Ulcerative, lichenoid mucositis
(current case)
Mouth ulceration1
Oral candidiasis2
Sialadenitis3
TNF-a inhibitors Lichen planuselike reactions4,5
Erythema multiforme6
Oral candidiasis7
Pemphigus vulgaris8
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tassium hydroxide preparation and fungal culture,
and no response to oral fluconazole.
Unlike erosive oral LP that typically manifests with
lesions on buccal mucosa, gingivae, and tongue that
tend to run a chronic course, the lesions in our
patient were located on the lip and noted during a
short course of secukinumab. As highlighted in
Table I, LP-like reactions have developed secondaryto use of TNF inhibitors.4,5 These reactions arose
most commonly within 2 months (range, 3 weeks to
16 months) of TNF inhibitor therapy. Oral LP in
patients on TNF inhibitor therapy manifested with
Wickham’s striae, with only 3 reports of erosive
disease.4,5 Wickham’s striae were not noted in our
patient. Unlike this case, most TNF inhibitoreasso-
ciated cases presented also with cutaneous LP, and
lesions were not exquisitely painful. TNF-a levels are
elevated in saliva and serum of patients with LP;
therefore, the appearance of oral LP in the context of
TNF-a blockade is paradoxical. TNF-a inhibition
leads to upregulation of interferon-a, a pro-
inflammatory cytokine implicated in LP.4 It is
possible that antieIL-17 drugs, which counteract
the synergistic effects of IL-17 and TNF-a,9 can
provoke a similar reaction.
Our patient was not on any other drugs known to
cause oral LP-like reactions.10 Methotrexate can
cause mucositis, which typically affects several sites
and is associated with cutaneous involvement, he-
matologic abnormalities, and keratinocyte dystro-
phy.11 These features were absent in our case. Our
patient was on methotrexate long before the lesions
developed, and lesions resolved after discontinua-
tion of secukinumab despite continued metho-
trexate treatment. Our patient was not using any
topical medications that could have caused lichenoid
contact dermatitis at the time that the labial lesions
developed.
Additional diagnoses considered include EM,
aphthae, PV, and MMP. Features of EM such as white
pseudomembranes and targetoid and necrotic le-
sions were missing in our case, and the 3-month
duration without periods of healing was not consis-
tent with EM. Furthermore, EM diagnosis was not
supported by the histopathologic findings. Typical
features of major aphthae, such as a large, discrete,
deep ulcers with yellow cratered base and
healing with scarring were not noted in this case.12
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necrosis, presence of neutrophils below the ulcer,
and involvement of salivary glands were absent.
Furthermore, our case did not show features of
complex aphthosis, such as almost constant pres-
ence of $ 3 oral aphthae. Our patient had no
vesiculobullous lesions affecting the skin or other
mucosal surfaces, and direct immunofluorescence
ruled out immunobullous disease such as PV and
MMP.
An association between secukinumab and labial
lesions in this case is supported by the onset of lesions
shortly after secukinumab administration and resolu-
tion after discontinuation of the drug. The underlying
mechanism of our patient’s labial lesions may be
similar to that proposed for TNF inhibitoreassociated
oral LP (upregulation of interferon-a),4 because IL-17
inhibitors downregulate the synergy of IL-17 with
TNF-a.9 Furthermore, decreased IL-17epositive
cells are seen in oral LP when compared with
nonspecifically inflamed mucosa,13 and it is possible
that drugs such as secukinumab may enhance a
similar disturbance in local immune regulation,
causing oral lichenoid reactions. As additional
antieIL-17 drugs are approved, it is important to
further characterize such adverse events. Clinicians
must be aware of this possible class effect, as early
diagnosis helps decrease morbidity, given the
extended time to recovery in our patient and the
potential for significant quality-of-life disruption with
these painful labial lesions.REFERENCES
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